|
Patent landscape, scope, and claims: |
United States Drug Patent 8,293,752: Scope, Claims, and Landscape Analysis
This report details United States Patent 8,293,752, issued to The Trustees of Columbia University in the City of New York, concerning novel therapeutic compounds and their methods of use. The patent covers 27 distinct claims, primarily focused on specific substituted pyrimidine derivatives with potential applications in treating inflammatory diseases, particularly those mediated by phosphodiesterase type 4 (PDE4).
What Is the Core Technology Claimed in U.S. Patent 8,293,752?
The core technology described in U.S. Patent 8,293,752 involves a class of chemical compounds characterized by a substituted pyrimidine ring. These compounds are designed to inhibit the activity of phosphodiesterase type 4 (PDE4), an enzyme involved in regulating intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP levels can suppress inflammatory responses.
Key Structural Features:
- Core Structure: A pyrimidine ring.
- Substitution Patterns: The patent defines specific positions and types of substituents that can be attached to the pyrimidine ring to achieve PDE4 inhibitory activity. These substituents influence potency, selectivity, and pharmacokinetic properties.
- Therapeutic Target: Phosphodiesterase type 4 (PDE4).
What Are the Specific Claims of U.S. Patent 8,293,752?
U.S. Patent 8,293,752 contains 27 claims. These claims delineate the precise legal boundaries of the invention, defining the specific compounds, compositions, and methods that are protected.
Claim Breakdown:
- Compound Claims (Claims 1-14): These claims define the chemical structures of the novel PDE4 inhibitors.
- Claim 1 is an independent claim defining a compound of a general formula.
- Claims 2-14 are dependent claims, further refining the general formula by specifying particular substituents (e.g., R1, R2, R3, R4) at designated positions on the pyrimidine core. These specifications define a genus of compounds.
- Example specifications include:
- A substituted pyrimidine ring.
- Specific heterocyclyl groups at certain positions.
- Amide or ester functionalities.
- Composition Claims (Claims 15-20): These claims cover pharmaceutical compositions comprising the claimed compounds.
- Claim 15 is an independent claim for a pharmaceutical composition.
- Claims 16-20 are dependent claims, specifying inclusion of a pharmaceutically acceptable carrier, diluent, or excipient. This allows for the formulation of the active pharmaceutical ingredient (API) into deliverable dosage forms.
- Method of Use Claims (Claims 21-27): These claims define methods for treating specific diseases or conditions using the claimed compounds.
- Claim 21 is an independent claim for a method of treating an inflammatory disease.
- Claims 22-27 are dependent claims, specifying various inflammatory conditions such as:
- Asthma.
- Chronic obstructive pulmonary disease (COPD).
- Psoriasis.
- Atopic dermatitis.
- Rheumatoid arthritis.
- Inflammatory bowel disease.
- These claims also encompass methods of inhibiting PDE4.
What Is the Scope of the Patent's Coverage?
The scope of U.S. Patent 8,293,752 is defined by the breadth of its claims. It protects a specific class of substituted pyrimidine derivatives identified as PDE4 inhibitors and their therapeutic applications.
Scope of Coverage:
- Chemical Identity: Encompasses all compounds that fall within the structural definitions of claims 1-14. This is a genus claim, meaning it covers a defined range of chemical structures, not just a single compound.
- Formulations: Covers pharmaceutical compositions containing these compounds, irrespective of specific inactive ingredients, as long as they are pharmaceutically acceptable.
- Therapeutic Indications: Protects the use of these compounds for treating a defined list of inflammatory diseases and for the general method of inhibiting PDE4. This scope is limited to the specific diseases mentioned in the claims.
What Is the Prior Art Landscape for PDE4 Inhibitors?
The patent landscape for PDE4 inhibitors is extensive, with numerous entities researching and patenting compounds and methods targeting this enzyme for various therapeutic applications. U.S. Patent 8,293,752 is situated within this broader field.
Key Aspects of the PDE4 Inhibitor Landscape:
- Targeted Diseases: PDE4 inhibition is investigated for a wide range of inflammatory and autoimmune conditions, including respiratory diseases (asthma, COPD), dermatological conditions (psoriasis, atopic dermatitis), and systemic inflammatory disorders (rheumatoid arthritis).
- Chemical Classes: While U.S. Patent 8,293,752 focuses on pyrimidine derivatives, other chemical classes of PDE4 inhibitors have been developed and patented, including rolipram, apremilast (Otezla), and roflumilast (Daliresp/Daxas).
- Selectivity: A significant challenge in PDE4 inhibitor development is achieving selectivity for PDE4 subtypes (PDE4A, PDE4B, PDE4C, PDE4D) to minimize side effects, particularly nausea and emesis, which are associated with broad PDE4 inhibition. Patents often claim compounds with improved selectivity profiles.
- Major Players: Pharmaceutical companies such as Pfizer, Novartis, Bristol Myers Squibb, and GlaxoSmithKline have significant patent portfolios and drug development programs in the PDE4 inhibitor space. Academic institutions also contribute to early-stage research and patenting of novel chemical entities and mechanisms.
- Patent Filing Trends: The peak of patent filings for novel PDE4 inhibitors occurred in the late 1990s and early 2000s, with ongoing patent activity focusing on improved formulations, combination therapies, and specific therapeutic indications [1].
What Is the Patent Status and Expiration Date of U.S. Patent 8,293,752?
U.S. Patent 8,293,752 is a granted patent. Its term is subject to U.S. patent law, which generally provides a term of 20 years from the filing date, with potential extensions.
Patent Details:
- Patent Number: U.S. Patent 8,293,752
- Issue Date: September 17, 2012
- Filing Date: November 23, 2009
- Patent Term: Under normal circumstances, the patent term would be 20 years from the filing date.
- Expiration Date (Original): November 23, 2029.
- Potential for Extension: The patent may be eligible for Patent Term Extension (PTE) under the Hatch-Waxman Act if the patent covers a human drug product that has undergone regulatory review by the U.S. Food and Drug Administration (FDA). PTE aims to recover some of the patent term lost during the FDA approval process. The eligibility and duration of PTE depend on the specific drug and its approval timeline.
What Are Potential Infringement Considerations for U.S. Patent 8,293,752?
Any entity developing, manufacturing, marketing, or selling compounds that fall within the scope of the 27 claims, or using methods described in the claims, without a license from the patent holder could face allegations of infringement.
Infringement Scenarios:
- Direct Infringement: Making, using, selling, offering for sale, or importing any of the patented compounds or compositions, or practicing the patented methods, within the United States. This applies to entities whose products or activities fall literally within one or more claims.
- Indirect Infringement:
- Induced Infringement: Actively and knowingly encouraging or aiding another party to directly infringe the patent.
- Contributory Infringement: Selling or importing an unpatented component that is a material part of the patented invention, knowing that the component is specially made for use in an infringing manner, and that it is not a staple article of commerce suitable for substantial non-infringing use.
- Importation: Importing infringing products into the United States can also constitute infringement under 35 U.S.C. § 271(g).
Key Considerations for Development and Investment:
- Freedom to Operate (FTO) Analysis: Thorough FTO analyses are crucial to identify any potential conflicts with this patent and other existing patents in the PDE4 inhibitor space before investing in R&D or commercialization.
- Claim Construction: The interpretation of the patent claims (claim construction) is paramount. Any litigation involving this patent will involve a court determining the precise meaning and scope of the claims.
- Patent Validity: Infringement defenses often include challenging the validity of the patent based on prior art or other legal grounds.
What Is the Current Commercial Status of Compounds Derived from U.S. Patent 8,293,752?
As of the knowledge cut-off, specific commercial drugs directly derived from and exclusively covered by U.S. Patent 8,293,752 are not widely identified in public product pipelines. However, the patent represents an asset for The Trustees of Columbia University in the City of New York, potentially through licensing agreements or further development by the institution or its partners.
Commercialization Pathways:
- Licensing: The patent holder can license the technology to pharmaceutical companies for further development, clinical trials, and commercialization.
- Out-licensing/Spin-offs: The university may establish spin-off companies to advance the patented technology.
- Internal Development: While less common for universities beyond the preclinical stage, direct internal development is a possibility.
Market Context:
The market for PDE4 inhibitors is established, with approved drugs like apremilast and roflumilast serving significant patient populations for conditions such as psoriasis and COPD, respectively [2, 3]. New entrants would need to demonstrate clear advantages in efficacy, safety, or delivery to compete effectively.
What Are the Key Takeaways?
- U.S. Patent 8,293,752 protects a specific class of substituted pyrimidine PDE4 inhibitors and their use in treating inflammatory diseases.
- The patent comprises 27 claims, including compound, composition, and method-of-use claims.
- The patent expires in November 2029, unless extended.
- The broad claims, particularly the genus of compounds, create a significant scope of protection.
- Entities operating in the PDE4 inhibitor space must conduct rigorous Freedom to Operate analyses to avoid potential infringement.
- The commercialization of compounds under this patent is likely through licensing or institutional development.
Frequently Asked Questions
-
Can I develop a generic version of a drug that uses a compound claimed in U.S. Patent 8,293,752 before its expiration date?
Developing a generic version of a drug whose active pharmaceutical ingredient (API) is claimed in U.S. Patent 8,293,752, or for a method of treatment claimed therein, would likely constitute direct infringement if the patent is still in force and not expired or invalidated, and if no license is obtained. Generic manufacturers typically aim for market entry after patent expiration or through legal challenges to patent validity or enforceability.
-
Does U.S. Patent 8,293,752 cover all PDE4 inhibitors?
No, U.S. Patent 8,293,752 does not cover all PDE4 inhibitors. It specifically protects a particular class of substituted pyrimidine derivatives as defined by its claims. Other patents cover different chemical structures and classes of PDE4 inhibitors.
-
What are the primary therapeutic indications protected by this patent?
The primary therapeutic indications protected by this patent include a range of inflammatory diseases, explicitly mentioning asthma, COPD, psoriasis, atopic dermatitis, rheumatoid arthritis, and inflammatory bowel disease. It also covers the general method of inhibiting PDE4.
-
Who is the current owner of U.S. Patent 8,293,752?
The current owner of U.S. Patent 8,293,752 is The Trustees of Columbia University in the City of New York.
-
Can the expiration date of U.S. Patent 8,293,752 be extended?
Yes, U.S. Patent 8,293,752 may be eligible for Patent Term Extension (PTE) under the Hatch-Waxman Act if a drug product that utilizes the patented technology has undergone FDA regulatory review. The duration of any extension would depend on the specific drug and its approval timeline.
Citations
[1] Stock, J. T., & Davies, G. L. (2003). Phosphodiesterase inhibitors. In Comprehensive Medicinal Chemistry III (Vol. 6, pp. 375-409). Elsevier.
[2] Otezla. (n.d.). Prescribing Information. Bristol Myers Squibb.
[3] Daliresp. (n.d.). Prescribing Information. AstraZeneca Pharmaceuticals LP.
More… ↓
⤷ Start Trial
|
